Current Status of Hepatocellular Carcinoma Treatment in Japan
- 71 Downloads
The Toward Integrated Treatment of Advanced Hepatocellular Carcinoma with Nexavar (TiTAN) Symposium was held in August 2010 in Tokyo, Japan, during which the position of sorafenib (Nexavar®) in the treatment of HCC in Japan (for which it received approval in 2009) was discussed by a panel of eight expert hepatologists in a session chaired by Dr Kudo. The following article focuses on the discussion that went on during this session, including question and answer sessions regarding the experiences of the 350 conference attendees in treating patients with HCC, as well as some of the more challenging disease management issues.
Since 2008, when the phase III Sorafenib Hepatocellular Carcinoma Assessment Randomized Protocol (SHARP) trial demonstrated an increase in the median overall survival (OS) for patients with unresectable HCC treated with sorafenib compared with placebo, international and Japanese guidelines recommend sorafenib as a first-line option for patients with advanced HCC Child-Pugh liver function class A who have extrahepatic metastasis. Sorafenib is also recommended for patients unresponsive to transarterial chemoembolization (TACE) or hepatic arterial infusion chemotherapy (HAIC). Importantly, if HCC is judged to be unresponsive to TACE, treatment should be switched to sorafenib in a timely manner.
Almost half of the conference attendees said that they used both the Japan Society of Hepatology clinical practice guidelines and the clinical practice guidelines for HCC when determining treatment strategies for individual HCC patients. Sorafenib should currently not be used as adjuvant therapy or in combination with TACE or HAIC until evidence from ongoing clinical trials shows that it is beneficial in these settings.
KeywordsSorafenib Tace Vascular Invasion Extrahepatic Metastasis Barcelona Clinic Liver Cancer
Unable to display preview. Download preview PDF.
- 1.Bayer Healthcare Pharmaceuticals. Nexavar approved in Japan for the treatment of advanced liver cancer. 2009 [cited; Available from: http://press.bayerhealthcare.com/en/press/auth/news-details-page.php/13182/2009-0239
- 3.The Japan Society of Hepatology. The Japanese HCC Clinical Practice Guideline. Treatment algorithm for hepatocellular carcinoma. Hepatology Research 2010; 40 (Suppl. 1): 8–9Google Scholar
- 5.Bruix J, Sherman M. AASLD Practice Guideline: Management of Hepatocellular Carcinoma: An Update. Available at http://www.aasld.org/practiceguidelines/Documents/Bookmarked%20Practice%20Guidelines/HCCUpdate2010.pdf (Accessed 14 Nov 2010). Hepatology 2010; July: 1–35Google Scholar
- 8.Sherman M, Mazzaferro V, Amadori D, et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma and vascular invasion or extrahepatic spread: A subanalysis from the SHARP trial. J Clin Oncol 2008; 26 (May 20 suppl): abstract 4584Google Scholar
- 18.Galle P, Blanc J, Van Laethem J-L, et al. Efficacy and safety of sorafenib in patients with hepatocellular carcinoma and prior anti-tumor therapy: a subanalysis from the SHARP trial. 43rd annual meeting of the European Association for the Study of the Liver (EASL 2008) Milan, Italy April 23–27, 2008 2008 [cited; Available from: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18817997
- 20.Bayer HealthCare Pharmaceuticals Inc. Sorafenib. Prescribing information. Available at http://www.nexavar.com/html/download/Nexavar_PI.pdf Accessed 2 December 2010. 2009
- 21.Ueshima K, Kudo M, Tanaka M, et al. Session 11-05, Phase I study of sorafenib in combination with low-dose cisplatin and fluorouracil intra-arterail infusion chemotherapy. Osaka, Japan: The 2nd Asia-Pacific Primary Liver Cancer Expert Meeting-A Bridge to Consensus on HCC Management, 2011Google Scholar
- 22.Kudo M. Molecular Targeted Therapy of Hepatocellular Carcinoma. Tokyo: Arc Media, 2010Google Scholar
- 23.Kudo M, Imanaka K, Chida N, et al. Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma. Eur J Cancer 2011; (14): 2117–27Google Scholar